A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients

GlaxoSmithKline (GSK)

Status: Terminated

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT00331292

CRB100706

Details and patient eligibility

About

The primary goal of this study is to identify a gene or panel of genes which are differentially expressed in lung cells and tissue from asthmatic patients following administration of Ipratropium bromide and eiTher nebulised Albuterol or saline. Each subject in this study will undergo two bronchoscopies.

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have a history of intermittant asthma.
• Have asthma symptoms less than once per week.
• Have no other significant disease.
• Do not take regular oral or inhaled steroids.
• Are a non-smoker for the past 12 months with a pack history of less than 5 years.

Exclusion criteria

• Have a history of drug or alcohol abuse.
• Have poorly controlled asthma or a history of life-threatening asthma.
• Have a history of hypersensitivity to bronchodilators.
• Are unable to abstain from inhaled steroids from 14 days prior to the first study visit until completion of the study.
• Have received oral steroids within 3 months of study entry.
• Have been hospitalized for your asthma within 3 months of study entry.
• Have had treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication.